betway必威登陆网址 (betway.com )学报››2022,Vol. 43››Issue (7): 548-552.DOI:10.3969/j.issn.2097-0005.2022.07.015
收稿日期:
2022-02-24出版日期:
2022-07-25发布日期:
2022-08-24通讯作者:
李晓梅作者简介:
刘婵,硕士研究生,住院医师,主要从事肿瘤病理学研究,E-mail:391234066@qq.com。基金资助:
Received:
2022-02-24Online:
2022-07-25Published:
2022-08-24Contact:
Xiaomei LI摘要:
STK33是丝氨酸/苏氨酸激酶的成员,近年来其在生物学领域尤其是肿瘤学方向的讨论热度正逐渐升高。虽然STK33在正常组织中的表达不具备普遍性,却能特异性表达于多种肿瘤中,通过不同的信号转导通路影响肿瘤细胞的众多生物学行为,对肿瘤的恶性进展起到促进作用。综合对STK33的研究现状,对于STK33在肿瘤中参与调节的分子机制虽然尚存在分歧,但其促癌的特性是被广泛认可的,STK33仍有望作为新的靶点,在肿瘤的分子靶向治疗中发挥重要作用。
刘婵, 李晓梅. STK33在肿瘤中表达的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(7): 548-552.
Chan LIU, Xiaomei LI. Advances in the expression of STK33 in tumors[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(7): 548-552.
1 | Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains[J]. Science, 1988, 241(4861): 42. |
2 | 陈淼, 陈晓婉, 洪雪辉, 等. 蛋白激酶小分子抑制剂在肿瘤治疗中的研究进展[J]. 中国肿瘤临床, 2020, 47(10): 523. |
3 | Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions[J]. Mol Cancer, 2018, 17(1): 48. |
4 | 谭春玉, 刘嘉伟, 程鹏, 等. STK家族在肿瘤中的研究进展[J]. 解剖科学进展, 2019, 25(1): 109. |
5 | Amid C, Bahr A, Mujica A, et al. Comparative genomic sequencing reveals a strikingly similar architecture of a conserved syntenic region on human chromosome 11p15.3 (including gene ST5) and mouse chromosome 7[J].Cytogenet Cell Genet, 2001, 93(3-4):284. |
6 | Mujica AO, Hankeln T, Schmidt ER. A novel serine/threonine kinase gene, STK33, on human chromosome 11p15.3[J]. Gene, 2001, 280(1/2): 175. |
7 | Mujica AO, Brauksiepe B, Saaler-Reinhardt S, et al. Differential expression pattern of the novel serine/threonine kinase, STK33, in mice and men[J]. FEBS J, 2005, 272(19): 4884. |
8 | Reuss S, Brauksiepe B, Disque-Kaiser U, et al. Serine/threonine-kinase 33 (Stk33)-component of the neuroendocrine network?[J]. Brain Res, 2017, 1655: 152. |
9 | Martins LR, Bung RK, Koch S, et al. Stk33 is required for spermatid differentiation and male fertility in mice[J]. Dev Biol, 2018, 433(1): 84. |
10 | Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome[J]. Science, 2002, 298(5600): 1912. |
11 | Brauksiepe B, Mujica AO, Herrmann H, et al. The Serine/threonine kinase Stk33 exhibits autophosphorylation and phosphorylates the intermediate filament protein Vimentin[J]. BMC Biochem,2008, 9: 25. |
12 | Ishida A, Sueyoshi N, Shigeri Y, et al. Negative regulation of multifunctional Ca2+/calmodulin-dependent protein kinases: physiological and pharmacological significance of protein phosphatases[J]. Br J Pharmacol, 2008, 154(4): 729. |
13 | Scholl C, Fröhling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells[J]. Cell, 2009, 137(5): 821. |
14 | O'Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer[J]. Nat Rev Genet, 2017, 18(10): 613. |
15 | Azoitei N, Hoffmann CM, Ellegast JM, et al. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33[J]. J Exp Med, 2012, 209(4): 697. |
16 | Luo TP, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability[J]. Proc Natl Acad Sci U S A, 2012, 109(8): 2860. |
17 | Weïwer M, Spoonamore J, Wei JQ, et al. A potent and selective quinoxalinone-based STK33 inhibitor does not show synthetic lethality in KRAS-dependent cells[J]. ACS Med Chem Lett, 2012, 3(12): 1034. |
18 | Lindsay CR, Jamal-Hanjani M, Forster M, et al. KRAS: reasons for optimism in lung cancer[J]. Eur J Cancer, 2018, 99: 20. |
19 | Babij C, Zhang YH, Kurzeja RJ, et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells[J]. Cancer Res, 2011, 71(17): 5818. |
20 | Mukhopadhyay S, Vander Heiden MG, McCormick F. The metabolic landscape of RAS-driven cancers from biology to therapy[J]. Nat Cancer, 2021, 2(3): 271. |
21 | Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7. |
22 | Lu Y, Tang J, Zhang WM, et al. Correlation between STK33 and the pathology and prognosis of lung cancer[J]. Oncol Lett, 2017, 14(4): 4800. |
23 | Wei XQ, Lei YJ, Li MJ, et al. miR-107 inhibited malignant biological behavior of non-small cell lung cancer cells by regulating the STK33/ERK signaling pathwayin vivoandvitro[J]. J Thorac Dis, 2020, 12(4): 1540. |
24 | Meng J, Chang CC, Chen YH, et al. EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC[J]. Onco Targets Ther, 2019, 12: 6033. |
25 | Sun EL, Liu CX, Ma ZX, et al. Knockdown of human serine/threonine kinase 33 suppresses human small cell lung carcinoma by blocking RPS6/BAD signaling transduction[J]. Neoplasma, 2017, 64(6): 869. |
26 | An HK, Chung KM, Park H, et al. CASP9 (caspase 9) is essential for autophagosome maturation through regulation of mitochondrial homeostasis[J]. Autophagy, 2020, 16(9): 1598. |
27 | Mocan L. Surgical management of gastric cancer: a systematic review[J]. J Clin Med, 2021, 10(12): 2557. |
28 | Mittal V. Epithelial mesenchymal transition in tumor metastasis[J]. Annu Rev Pathol, 2018, 13: 395. |
29 | Kong FY, Sun T, Kong XY, et al. Krüppel-like factor 4 suppresses serine/threonine kinase 33 activation and metastasis of gastric cancer through reversing epithelial-mesenchymal transition[J]. Clin Cancer Res, 2018, 24(10): 2440. |
30 | Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colorectal cancer[J]. Int J Mol Sci, 2022, 23(2): 852. |
31 | Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality[J]. Gut, 2017, 66(4): 683. |
32 | Moon JW, Lee SK, Lee JO, et al. Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer[J]. J Exp Clin Cancer Res, 2014, 33(1):4. |
33 | Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics[J]. Trends Genet, 2000, 16(4): 168. |
34 | Yin MD, Ma SP, Liu F, et al. Role of serine/threonine kinase 33 methylation in colorectal cancer and its clinical significance[J]. Oncol Lett, 2018, 15(2): 2153. |
35 | Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023. |
36 | Yang T, Song B, Zhang J, et al. STK33 promotes hepatocellular carcinoma through binding to c-Myc[J]. Gut, 2016, 65(1): 124. |
37 | Moore A, Donahue T. Pancreatic cancer[J]. JAMA, 2019, 322(14): 1426. |
38 | Kong FY, Kong XY, Du YQ, et al. STK33 promotes growth and progression of pancreatic cancer as a critical downstream mediator of HIF1α[J]. Cancer Res, 2017, 77(24): 6851. |
39 | Liu Y, Steinestel K, Rouhi A, et al. STK33 participates to HSP90-supported angiogenic program in hypoxic tumors by regulating HIF-1α/VEGF signaling pathway[J]. Oncotarget, 2017, 8(44): 77474. |
40 | Zhou B, Xiang J, Zhan CY, et al. STK33 promotes the growth and progression of human pancreatic neuroendocrine tumour via activation of the PI3K/AKT/mTOR pathway[J]. Neuroendocrinology, 2020, 110(3/4): 307. |
41 | Jaffe ES. Diagnosis and classification of lymphoma: impact of technical advances[J]. Semin Hematol, 2019, 56(1): 30. |
42 | Piccaluga PP, Navari M, De Falco G, et al. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas[J]. Oncotarget, 2016, 7(1): 224. |
43 | Roider T, Seufert J, Uvarovskii A, et al. Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels[J]. Nat Cell Biol, 2020, 22(7): 896. |
44 | Feng LL, Xu XF, Zhao KK. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma[J]. Leuk Res, 2021, 111: 106708. |
45 | Huang LY, Chen C, Zhang GD, et al. STK33 overexpression in hypopharyngeal squamous cell carcinoma: possible role in tumorigenesis[J]. BMC Cancer, 2015, 15: 13. |
46 | Zhong XD, Liu YN, Liu HM, et al. Identification of potential prognostic genes for neuroblastoma[J]. Front Genet, 2018, 9: 589. |
[1] | 李瑞娟, 孟艳红.超声造影联合O‐RADS在卵巢肿瘤诊断中的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(9): 712-715. |
[2] | 张欢欢, 张蕾, 崔洁, 梁尹攀, 伊淑莹.肿瘤免疫中Wnt/β‑catenin信号通路的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(9): 716-720. |
[3] | 王伟浩, 马莹, 李胜.循环肿瘤细胞形态诊断参数测量方法的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(8): 561-564. |
[4] | 张露, 赵乐乐, 解思凯, 李海鹏, 王俊杰, 李正红.嵌合抗原受体T细胞治疗女性高发恶性肿瘤的研究进展和挑战[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(8): 608-612. |
[5] | 韩明帅, 武英欣, 金讯波.循环肿瘤细胞在前列腺癌中的应用[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(8): 613-617. |
[6] | 李彬, 冯锋, 刘富垒.肿瘤切除手术诱发术后复发的机制及纠正策略研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(7): 535-540. |
[7] | 褚微, 张冰, 纪洪.HMGCS2在疾病中的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(7): 546-551. |
[8] | 司贵米, 山长平.外泌体非编码RNA在三阴性乳腺癌中的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(6): 461-465. |
[9] | 彭燕玲, 宋文刚, 刘春燕.PDCD5在消化系统肿瘤中的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(4): 300-303. |
[10] | 武英欣, 韩明帅, 张俊勇.3D技术在结直肠肿瘤诊疗中的应用[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(3): 237-240. |
[11] | 刘桐, 王西冉, 孙振, 于成龙, 张明宾.颏下岛状瓣修复口腔恶性肿瘤术后缺损的临床分析[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(1): 53-55. |
[12] | 李秀凤, 刘德美, 韩凯, 李云婷, 张云香.子宫内膜中肾腺癌1例及文献复习[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(1): 56-58. |
[13] | 于宗菲, 翁丽涵, 孙诚诚, 曹晓钰, 叶振.CRISPR/Cas9系统技术难关:脱靶效应及其优化方法[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(1): 74-80. |
[14] | 徐心悦, 景秀丽, 唐华.Ⅱ型固有淋巴细胞的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(9): 666-673. |
[15] | 王迪, 吴霜, 王倩, 杨静, 孟英涛.耳穴压豆改善恶性肿瘤伴失眠患者睡眠效果的Meta分析[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(7): 493-500. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||